Abstract
In this work, a semi-mechanistic tumour growth response model for gemcitabine in pancreatic (administered as single agent) and ovarian (given as single agent and in combination with carboplatin) cancer in mice was developed. Tumour profiles were obtained from nude mice, previously inoculated with KP4, ASPC1, MIA PACA2, PANC1 (pancreas), A2780 or SKOV3xluc (ovarian) cell lines, and then treated with different dosing schedules of gemcitabine and/or carboplatin. Data were fitted using the population approach with NONMEM 7.2. In addition to cell proliferation, the tumour progression model for both types of cancer incorporates a carrying capacity representing metabolite pool for DNA synthesis required to tumour growth. Analysis of data from the treated groups revealed that gemcitabine exerted its tumour effects by promoting apoptosis as well as decreasing the carrying capacity compartment. Pharmacodynamic parameters were cell-specific and overall had similar range values between cancer types. In pancreas, a linear model was used to describe both gemcitabine effects with parameter values between 3.26x10 -2 and 4.2x10 . The contribution of carboplatin to tumour effects was lower than the response exerted by gemcitabine and was incorporated in the model as an inhibition of the carrying capacity. The model developed was consistent in its structure across different tumour cell lines and two tumour types where gemcitabine is approved. Simulation-based evaluation diagnostics showed that the model performed well in all experimental design scenarios including dose, schedule, and tumour type.
Introduction
Nowadays, drug development constitutes a great deal in terms of the cost-efficacy relationship, especially in the oncology area where the attrition rate is very high; in fact, a recent review indicates that up to 95% of the compounds tested in early clinical phases do not reach marketing authorisation (Moreno and Pearson, 2013) . One approach to reduce cancer attrition rates is to look for strategies to better predict clinical trial outcome from early preclinical information (Zhang et al., 2006) . In this context, preclinical (semi) mechanistic pharmacokinetic/pharmacodynamics (PKPD) analysis could be considered as a critical phase to understand the effect of a drug and its correlation to the clinic, taking into account that despite several successful applications (Claret et al., 2013; Stein et al., 2012; Wang et al., 2009) , modelling response data in oncology presents more limitations than in other therapeutic areas (Mould et al., 2015) . Recently, it has been shown that models developed in the in vivo preclinical setting can drive the model structure in the clinical scenario where data are in general sparse and conditioned by high drop-out rates (Ouerdani et al., 2015) . In addition, other works have shown that it is possible to scale-up relevant model-derived descriptors and model parameters from animal to human either for efficacy or hematotoxicity (Friberg et al., 2010; Rocchetti et al., 2007) .
This work is focused on studying the pharmacodynamics of the anticancer drug Gemcitabine in xenograft mice models. Gemcitabine, a cytotoxic/cytostatic antimetabolite, is a pro-drug of the active form (dFdCTP) which inhibits cell growth and induces apoptosis through incorporation into replicated DNA (Hui and Reitz, 1997; Storniolo et al., 1997; Teicher, 2007) . It is approved in the treatment of locally advanced or metastatic pancreatic cancer as single agent and in the treatment of non-small-cell lung, breast and ovarian cancer in combination (Hui and Reitz, 1997) .
Information regarding Gemcitabine dose-response relationship and the factors contributing to its magnitude of response is still limited. To the best of our knowledge there is a lack of publicly available reports dealing with the PKPD characteristics of gemcitabine apart from the recent in vivo pre-clinical analysis in breast cancer xenografts (Yuan et al., 2015) , and
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the mechanistic models developed with in vitro data (Hamed et al., 2013; Miao et al., 2016; Zhu et al., 2015) . Regarding clinical PKPD models, the effect of gemcitabine administered in combination in non-small cell lung, breast and ovarian cancer patients have been described linking model predicted changes in tumour size with overall survival (Tate C et al., 2013; Tham et al., 2008; Zecchin et al., 2016) .
The goal of this study is to develop a semi-mechanistic tumour growth model to describe the effects of gemcitabine in both pancreas (administered as a single agent) and ovarian (given in combination with carboplatin) mouse xenograft models, including different tumour cell lines for both types of tumour. Our aim was to select a common model structure for all experimental conditions (cell lines, tumour type, single vs combination therapy, and dosing schedule) providing a robust reference for future translational purposes. This work appears timely given recent articles where the concentration-response of gemcitabine in combination with other anti-cancer drugs has been evaluated at the in vitro (Hamed et al., 2013; Miao et al., 2016; Zhu et al., 2015) , and in vivo pre-clinical (Yuan et al., 2015) and clinical levels (Tate C et al., 2013; Tham et al., 2008; Zecchin et al., 2016) .
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Model building
Data corresponding to each of the different tumour cell lines (either pancreas or ovarian)
were analysed separately. Within each cell line, tumour measurements obtained from different studies were pooled and analysed together. A more appropriate procedure would have been to pool all data together for a joint modelling exercise of all cells lines, and use the type of cell line as a categorical covariate. However when we tried that approach, we faced the complexity of estimating a great number of parameters, and we did not manage to get convergence and parameter estimates in the analyses.
Model development was performed sequentially. First, the disease progression model (i.e., tumour dynamics in the absence of treatment) was characterised, and then the model for drug effects was established (see below). At each modelling step all model parameters were re-estimated.
This article has not been copyedited and formatted. The final version may differ from this version. inter-compartment clearance, respectively, and V n is the distribution volume in each compartment. In the case of carboplatin, a one compartment model was used and the estimates of the pharmacokinetic parameters were obtained from literature (Wang et al., 2004a; Wang et al., 2004b) . During the analysis, the mean pharmacokinetic population parameters were used to simulate typical drug concentration vs time profiles in plasma corresponding to each drug and dosing schedule, which were used to describe the drug effects of tumour dynamics. It was assumed that (i) drug absorption after i.p administration was fast and complete (and treated as an intravenous bolus injection), and independent from the dose level and time, and (ii) there was not pharmacokinetic interaction between gemcitabine and carboplatin (Wang et al., 2004a; Wang et al., 2004b) .
In the following, the selected model is described in detail. However, during the model building exercise several other models and variants were also explored, as indicated in the results section.
Disease progression model
Different disease progression models were explored and are represented in Table 1 ( Claret et al., 2009; Frances et al., 2011; Simeoni et al., 2004; Wang et al., 2009) . The model providing the best description of the data regardless of the type of cancer cell lines was the model published by Hahnfeldt (Hahnfeldt, 1999) , in which nutrient supply represents a key 
Where T and K represent the tumour volume and the carrying capacity, the latter representing nutrient supply. 1 and 2 are the first order rate constants of tumour proliferation and carrying capacity degradation. The parameters B and D account for the stimulatory and negative feedback mechanisms of tumour volume on the dynamics of the carrying capacity.
Drug effect model

Gemcitabine
The selected model describing gemcitabine response consists of two different effects: (i) E Gem1 , promoting apoptosis within the tumour, and (ii) E Gem2 , decreasing the source of nutrients.
E Gem1 , was found to be delayed compared to the predicted typical time course of gemcitabine in plasma (Cp Gem ). Delayed response was characterised by a chain of three transit compartments as described by the next set of differential equations, where TR 1-3 are the predicted concentration/active signal in each of the transit compartments. K TR , is the first order rate constant of transfer between transit compartments.
E Gem1 has the form of f(TR 3 ), where f() represents linear or non-linear expressions of TR 3 , and was incorporated into the tumour model as:
The second mechanism of action, represented by E Gem2 , could be linked directly to the 
Gemcitabine and carboplatin
The model for combination treatment incorporates the effect of carboplatin (E Carbo ), through a decrease in the nutrient supply, therefore impairing tumour progression, as indicated in equation 9:
Where E Carbo has the general form of h(Cp Carbo ), where Cp Carbo is the predicted carboplatin concentration in plasma, and h() represents a linear or non-linear expression of Cp Carbo.
The initial conditions for the tumour volume (T 0 ) and carrying capacity (K 0 ) compartments were estimated during the modelling analysis, while the corresponding values of TR 1-3 were set to 0. The model is represented schematically in figure 2 using the example of ovarian cancer, including the combination therapy.
Model selection
Selection between models was mainly based on the minimum value of the objective function (MOFV) provided by NONMEM which is approximately equal to -2×log (likelihood) (-2LL).
On the other hand, non-nested models were compared using the Akaike Information Criteria (AIC) (Ludden et al., 1994) calculated as -2LL+2xNP, where NP is the number of parameters in the model. The model with the lowest value of AIC, given the precision of model parameters and an adequate description of the data, was selected.
It was also made through a visual exploratory analysis of the goodness of fit plots, and the meaningfulness of the parameter estimates, as well as their precision.
Model evaluation
Simulation-based diagnostics were used to evaluate model performance. Prediction corrected visual predictive checks (pc-Vpc) (Bergstrand et al., 2011) , and 97.5 th raw data percentiles. In addition, the precision of the parameter estimates was evaluated from the analysis of 500 simulated bootstrap data sets for each tumour cell line (Efron and Tibshirani, 1993).
Model exploration
As it is described in the results section, the PKPD models selected showed a certain degree 
Modelling tumour profiles
Model for tumour progression model
From the numerous alternatives available to describe tumour volume data in the absence of treatment (Claret et al., 2009; Frances et al., 2011; Simeoni et al., 2004; Wang et al., 2009) , a reduced version of the model proposed by Hahnfeldt (Hahnfeldt, 1999) provided the lowest value of AIC (see Table I ) and the best data description for the six different tumour cell lines.
The 2 parameter describing the first order rate constant of the degradation of K could not be estimated with precision from any control group and was therefore removed from the model with negligible effects on -2LL. The same happened with the D parameter describing the negative feedback of the tumour volume profile on the dynamics of K for the MIA PACA2
and PANC1 tumour cell lines. Typical estimates of parameters were in general of the same order of magnitude among the different cell lines, with the exception of K 0 which ranged from 3x10 -5 (PANC1) to 1.16x10 2 (SKOV3xluc). The covariate 'study' was tested for significant effects on all the model parameters and was found to be significant (p <0.001) for the SKOV3xluc ovarian tumour cell line on the T 0 and 1 parameters (see table I ).
Data supported the estimation of inter-animal variability on (i) 1 for all the six tumour cell lines with a magnitude ranging from 31 to 79% (MIA PACA2), and (ii) T 0 and K 0 for just the four pancreas tumour cell lines, where the magnitude was low-moderate except for MIA PACA2 (44%, T 0 ; 85% K 0 ). For the rest of parameters the incorporation of inter-animal variability did not reduce the value of -2LL significantly (p>0.05).
Models for drug effects
Once the model for tumour progression was established, model building was focused on the following main aspects: (i) selection of the mechanism(s) of action, (ii) characterisation of the onset of drug action and (iii) description of the concentration effect relationship. Table II lists the estimates of the parameters (and their precision) obtained from the selected model (see figure 2) describing drug effects as single agent or as combination therapy.
Single agent
Data were best described considering two different effects of gemcitabine: promoting tumour shrinkage through an apoptosis mechanism and decreasing the carrying capacity. By including both types of drug effects, the AIC value was significantly reduced ( Table I ). The two mechanisms of action differed on the time of onset; whereas the effect of the carrying capacity was linked directly with the change in drug exposure, apoptotic response appeared to be delayed with respect to dosing. The mean transit time calculated as (n+1)/K TR , where n is the number of transit compartments, varied from 0.8 (KP4) to 7 (SKOV3xluc) days. The exposure effect relationship was best characterised with a linear model for the case of all pancreas tumour cell lines, which showed a sensitivity represented by the θ SLOPE parameter
This article has not been copyedited and formatted. The final version may differ from this version. , respectively), and higher than any of the slope parameters estimated from the pancreas xenografts. This last result is clearly seen in the raw data represented in figure 1 where higher tumour effects are shown for ovarian xenografts. The effect on the carrying capacity was described with a linear model and appears to be lower than the apoptotic effect and of the same range as in the case of pancreas tumours.
Inter-animal variability in drug effect parameters could only be quantified for the case of pancreas xenografts on the parameters K TR and SLOPE, showing low to moderate magnitude, with the exception of K TR from MIA PACA2 (90%).
Combination
Different alternatives were explored to characterise the contribution of carboplatin to tumour shrinkage in ovarian xenografts. Carboplatin showed significant model improvement (p<0.001) when it was incorporated into the apoptotic (only for A2780 cell line) or the inhibitory carrying capacity effects; however it was not possible to keep both carboplatin effects in the model; and the effect on the carrying capacity was preferred based on the visual exploration of the goodness of fit plots (not shown) and on the reduction of the AIC (Table I ). The effect of carboplatin was greater for the A2780 than for SKOV3xluc, and in general of the same magnitude that gemcitabine showed on the same mechanism of action.
Inter-animal variability could not be estimated for the effects of carboplatin. 
Model exploration
The results from the current modelling exercise indicate that (i) tumor growth depends on a self-proliferation mechanism and a carrying capacity, (ii) gemcitabine exerts its drug action through two mechanisms of action, (iii) there is a contribution of carboplatin to the tumor shrinkage elicited by gemcitabine, (iv) drug effects appear to be exposure-dependent, and The PKPD characteristics of gemcitabine have been studied to some extent in vitro and in in vivo pre-clinical experiments. In vitro models developed on pancreatic cells estimated two types of effects for gemcitabine, inhibiting cell cycle progression and inducing apoptosis (Hamed et al., 2013; Miao et al., 2016; Zhu et al., 2015) . Those analyses were performed at concentrations of gemcitabine ranging from 0 to 100 mg/L while in the present work, the simulated concentrations of gemcitabine range from 50 to 700 mg/L. In those in vitro experiments, drug combinations were also considered; the interactions of gemcitabine with trabectecin and birinapant were described as synergistic. The model presented in this work is able to reproduce in vivo the two different effects for gemcitabine described in vitro, albeit with a different model structure. Yuan et al developed a semi-mechanistic PKPD model for gemcitabine in combination with dexametasone in breast cancer in mice (Yuan et al., 2015) .
They could identify a single mechanism of action for the case of gemcitabine, and reported pharmacodynamic parameters that were in accordance with those found in our study for the 2016). In their work, both drugs had additive effects (driven by drug exposure) promoting apoptosis, making the tumour more sensitive to gemcitabine effects. Those results are also supported by the current model as in Figure 6 , showing that contribution of carboplatin to tumour effects is lower than the response exerted by gemcitabine. However, it has to be taken into account that mouse data receiving carboplatin alone were not available.
We do believe this study provides a robust preclinical PKPD model that could be used in future analysis in terms of translational approaches. Pharmacodynamic parameters tend to This article has not been copyedited and formatted. The final version may differ from this version. IFT is an employee of the University of Navarra and MG-C is a Phd student from University of Navarra. CP and PWI are employees of Elli Lilly and Company.
This article has not been copyedited and formatted. The final version may differ from this version. Shrinkage % is indicated in ().*parameter fixed. SLOPEp corresponds to gemcitabine effect constant in pancreas cancer that drives both mechanisms; under tumour volume and under carrying capacity. Emax and Ce50 are the maximum effect and the potency of gemcitabine responsible of promoting the apoptosis mechanism in ovarian cancer. SLOPEo is gemcitabine effect constant that drives the effect under the carrying capacity in ovarian cancer. SLOPEc is carboplatin effect constant under the carrying capacity Table 1 Description of the PKPD model parameters. 
Parameters
)
First order rate constant for the spontaneous loss of the carrying capacity. 
SLOPE p (L/mg·day)
Gemcitabine effect constant in pancreas cancer that drives both mechanisms; under tumour volume and under carrying capacity. Emax (day -1
)
Maximum effect of gemcitabine responsible of promoting the apoptosis mechanism in ovarian cancer.
Ce50 (mg/L)
Potency of gemcitabine responsible of promoting the apoptosis mechanism in ovarian cancer.
SLOPE O (L/mg·day)
Gemcitabine effect constant that drives the effect under the carrying capacity in ovarian cancer.
Carboplatin effect SLOPE c (L/mg·day)
Carboplatin effect constant under the carrying capacity in ovarian cancer
